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Objective: To evaluate the serum levels of leptin and adiponectin in patients with sys-
temic lupus erythematosus (SLE) and correlate their levels with disease activity, presence
of  autoantibodies and clinical manifestations.
Methods: 52 women with SLE and 33 healthy women were evaluated. The patients were
divided into two groups, the ﬁrst with active SLE and the second with inactive SLE. Patients
with  SLEDAI ≥3 were considered active. Serum levels of leptin (ng/mL) and adiponectin
(g/mL) were measured by enzyme immunoassay.
Results: There was a signiﬁcant difference in leptin levels between SLE and controls
(20.7 ± 17.1 vs. 8.0 ± 5.0 ng/mL, p < 0.001), but no signiﬁcant difference in adiponectin lev-
els  (87 5 ± 69.7 vs. 118.1 ± 70.6 pg/mL, p = 0.053). No signiﬁcant difference in levels of leptin
and  adiponectin was noted between inactive and active SLE groups. There was a signiﬁcant
association between low levels of leptin and positivity for anticardiolipin (aCL) (p = 0.025)
and  lupus anticoagulant (LA) (p = 0.003) and a signiﬁcant association between high levels
of  leptin and the presence of renal disease (p < 0.001). However, there was no association
between adiponectin levels with autoantibodies and clinical features in SLE patients.
Conclusion: Patients with SLE had elevated leptin levels, with association with renal involve-
ment. Leptin and adiponectin were not correlated with disease activity. Low levels of leptinhave been associated with the presence of LA and aCL.
© 2014 Elsevier Editora Ltda. All rights reserved.∗ Corresponding author.
E-mail: vitalina.barbosa@gmail.com (V. de Souza Barbosa).
http://dx.doi.org/10.1016/j.rbre.2014.08.013
2255-5021/© 2014 Elsevier Editora Ltda. All rights reserved.
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Leptina  e  adiponectina  no  lúpus  eritematoso  sistêmico:  correlac¸ões
clínicas  e  laboratoriais
Palavras-chave:
Lúpus eritematoso sistêmico
Leptina
Adiponectina
r  e  s  u  m  o
Objetivo: Avaliar os níveis séricos de leptina e adiponectina em pacientes com lúpus eritem-
atoso sistêmico (LES) e correlacionar seus níveis com atividade inﬂamatória, presenc¸a  de
autoanticorpos e manifestac¸ões clínicas.
Métodos: Foram avaliadas 52 mulheres com LES e 33 mulheres saudáveis. As pacientes
foram divididas em dois grupos, o primeiro com LES ativo e o segundo com LES inativo.
Foram consideradas em atividade as paciente com Sledai ≥ 3. Os níveis séricos de leptina
(ng/mL) e adiponectina (ug/mL) foram medidos por ensaio imunoenzimático.
Resultados: Houve diferenc¸a signiﬁcativa nos níveis de leptina entre LES e controle
(20,7  ± 17,1 vs. 8,0 ± 5,0 ng/mL, p < 0,001), mas não houve diferenc¸a signiﬁcativa nos níveis
de  adiponectina (87,5 ± 69,7 vs. 118,1 ± 70,6 ug/mL, p = 0,053). Entre LES inativo e ativo, não
houve diferenc¸a signiﬁcativa dos níveis de leptina e adiponectina. Houve uma  associac¸ão
signiﬁcativa entre os baixos níveis de leptina e positividade para anticardiolipina (aCL)
(p  = 0,025) e anticoagulante lúpico (LA) (p = 0,003) e uma associac¸ão signiﬁcativa entre níveis
elevados de leptina e da presenc¸a de manifestac¸ão renal (p < 0,001). No entanto, não houve
associac¸ão  entre adiponectina com autoanticorpos e características clínicas nas pacientes.
Conclusão: Pacientes com LES apresentaram nível elevado de leptina, com associac¸ão ao
envolvimento renal. A leptina e a adiponectina não se correlacionaram com a atividade da
doenc¸a.  Baixos níveis de leptina foram associados com a presenc¸a de LA e aCL.
©  2014 Elsevier Editora Ltda. Todos os direitos reservados.
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mntroduction
n recent years, a major route linking metabolism and the
mmune system has been described, after veriﬁcation of an
nﬂammatory state in obesity.1 The adipose tissue is an organ
hat performs neuroendocrine and immune functions, pro-
ucing various cytokines that include IL-6 and TNF-alpha,
eptin, adiponectin and resistin, known as adipokines. These
ytokines participate in a variety of physiological processes,
uch as food intake, insulin sensitivity, atherosclerosis, immu-
ity and inﬂammation.2 They represent a new group of
roteins released from adipocytes, which act as modulators
f the immune system.3 Studies demonstrate the partici-
ation of these substances in rheumatic and inﬂammatory
iseases.4–7
Leptin acts on the immune system as a proinﬂammatory
ytokine. In animal models, its deﬁciency is associated with
n increased susceptibility to infection and reducing the
nﬂammation.8 It promotes the proliferation and activation of
 lymphocytes and induces production of Th1 cytokines.1,9,10
tudies have reported increased leptin levels in systemic lupus
rythematosus (SLE) patients.11–13
Adiponectin has anti-inﬂammatory action.14 It inhibits the
roliferation and activation of T lymphocytes, as well as lym-
hopoiesis and B lymphocytes.15 High levels of adiponectin
ere found in patients with SLE,12,16,17 although there is still
ontroversy.
The aim of this study was to evaluate the levels of leptin and
diponectin in patients with SLE and its possible correlation
ith disease activity, presence of autoantibodies and clinical
anifestations.Patients  and  methods
52 female patients who met  the American College of Rheuma-
tology (ACR) classiﬁcation criteria for SLE,18 hospitalized
and/or in outpatient care at the Rheumatology Department,
Hospital das Clínicas, Medicine School, Universidade Federal
de Goiás (HC/FM/UFG) were included.
The patients were divided into two subgroups: a subgroup
of patients with active SLE (n = 21) and another subgroup of
patients with inactive disease (n = 31). The control group com-
prised 33 healthy women matched for age. The exclusion
criteria were: patients younger than 18 years old, pregnancy,
history of myocardial infarction or diabetes, liver disease,
renal failure, prednisone >20 mg/day and body mass index
(BMI) >30 kg/m2.
The study was approved by the Research Ethics Committee
of the HC/UFG and all participants who agreed to participate
signed an informed consent form.
The evaluation of patients included demographics, age at
disease onset, disease duration, clinical manifestations and
physical examination. At the time of evaluation, lipid proﬁle,
fasting glucose and tests of inﬂammatory activity were also
obtained for each patient. Autoantibodies found in the clinical
record were considered; for those patients for whom autoan-
tibodies were not found, these were requested at the time of
their inclusion in the study.
To obtain the proﬁle of autoantibodies, ANA and anti-DNA
were used; these tests were performed at the Immuno-
Rheumatology Laboratory, HC/FM/UFG. ANA was obtained by
indirect immunoﬂuorescence on HEp-2 cells (Hemagen Diag-
nostics, Inc.) and anti-DNA by indirect immunoﬂuorescence
142  r e v b r a s r e u m a t o l . 2 0 1 5;5 5(2):140–145
Table 1 – Demographics, clinical and laboratory data of patients with SLE and controls.
Variables SLE (n = 52) Control (n = 33) p
Age, yearsa 33.4 (±9.4) 32.5 (±10.5) 0.670
Disease duration, yearsb 7.5
BMI, kg/m2 a 23.8 (±3.5) 21.8 (±2.5) 0.008
Glucose, mg/dLa 76.2 (±9.9) 84.2 (±8.5) <0.001
Total cholesterol, mg/dLa 178.1 (±41.7) 172.8 (±43.7) 0.575
HDL cholesterol, mg/dLa 50.6 (±15.9) 62.3 (±19.2) 0.003
LDL cholesterol, mg/dLa 98.2 (±26.4) 87.0 (±35.6) 0.102
Triglycerides, mg/dLa 140.3 (±94.0) 93.1 (±43.4) 0.008
SLE, systemic lupus erythematosus; BMI, body mass index; HDL, high density lipoprotein; LDL, low density lipoprotein.
Table 2 – Characteristics of patients with SLE (n = 52),
according to the disease activity.
Active SLE
(n = 21)
Inactive SLE
(n = 31)
p
Age, years* 33.4 (±9.9) 33.6 (±9.1) 0.861a
BMI, kg/m2 * 23.7 (±3.5) 24.0 (±3.6) 0.760a
Disease duration, years* 6.0 (±6.6) 9.0 (±6.4) 0.110a
ESR, mm/L2 h* 64.7 (±35.4) 31.8 (±21.6) <0.001a
ANA-positive, % 90.5% 93.5% 0.170b
Anti-ENA, % 85.7% 61.3% 0.056b
Anti-DNA, % 52.4% 35.5% 0.223b
LA, % 19% 9.7% 0.331b
aCL, % 14.3% 9.7% 0.610b
SLEDAI* 7.42 (±3.9) 0.20 (±0.8) <0.001c
SLE, systemic lupus erythematosus; BMI, body mass index; ESR,
erythrocyte sedimentation rate; ANA, antinuclear factor; Anti-ENA,
anti-extractable nuclear antigen antibody; LA, lupus anticoagulant;
aCL, anticardiolipin; SLEDAI, Systemic Lupus Erythematosus Dis-
ease Activity Index.
∗ Data presented as mean (±standard deviation).
aa Data presented as mean (±standard deviation).
b Data presented as mean.
on Crithidia lucillae. A survey of antibodies to extractable
nuclear antigens (ENA), anti-Ro, anti-La, anti-Sm and anti-
RNP, as well as to anticardiolipin, was performed in the
General Laboratory, HC/FM/UFG, by ELISA (Enzyme Linked
Immuno Sorbent Assay).
Disease activity was assessed at inclusion in the study,
using SLEDAI (Systemic Lupus Erythematosus Disease Activ-
ity Index).19 Patients with SLEDAI ≥3 were considered active.
In patients with disease activity, only anti-DNA and comple-
ment (C3 and C4) levels brought at the time of inclusion were
considered.
For the determination of leptin, the ELISA technique was
used, in a typical capture assay in two stages, or in “sandwich”,
according to the manufacturer’s instructions (DBC – Diagnos-
tics Biochem Canada). The assay sensitivity was 100 ng/mL.
The level of adiponectin was also obtained by ELISA in a quan-
titative sandwich, according to the manufacturer’s protocol
(MBL International Corp., Woburn, MA,  USA), and the sensi-
tivity of the assay was 100 pg/mL, with a mean recovery of
90–105% of adiponectin.
Statistical  analysis
All statistical analysis were performed using the Statistical
Package for Social Sciences (SPSS Inc., Chicago, IL) for Win-
dows, version 18. Student’s t-test was used for independent
samples; equivalent variances were deﬁned by Levene’s F-test.
The veriﬁcation of the normality of the distribution was done
by Kolgomorov and Smirnov test. The Mann–Whitney test was
used for quantitative variables that were not normally dis-
tributed. Correlations were calculated by Pearson correlation.
Categorical variables were analyzed by the chi-squared test (a
measure of association). For all statistical evaluations, p < 0.05
was considered statistically signiﬁcant.
Results
There was no statistical difference between the mean age of
SLE patients and controls (33.4 ± 9.4 years vs. 32.5 ± 10.5 years,
p = 0.670). The body mass index was higher in SLE patients
compared to controls (23.8 ± 3.5 kg/m2 vs. 21.8 ± 2.5 kg/m2,
p = 0.008). The metabolic evaluation between groups showed
no difference in levels of total and LDL cholesterol, but there
was a difference in blood glucose levels, HDL and triglycerides
(Table 1).t-Test.
b Chi-squared test.
c Mann–Whitney test.
Table 2 presents the characteristics of SLE patients with
active disease (n = 21). The mean age in the active SLE
group was similar to the group of patients with inactive SLE
(33.4 ± 9.9 years vs. 33.6 ± 9.1 years, p = 0.861). BMI  did not differ
between patients with active SLE and patients with inactive
disease (24.0 ± 3.6 kg/m2 vs. 23.7 ± 3.5 kg/m2, p = 0.760). Dis-
ease duration was not signiﬁcantly different between the two
groups (9.0 ± 6.4 years vs. 6.0 ± 6.6 years, p = 0.110). The mean
duration of disease activity was 5.6 months. With regards to
autoantibodies (ANA, anti-ENA, anti-DNA, LA and aCL), there
was no statistical difference between groups.
Adiponectin levels were lower in SLE patients, although
there was no signiﬁcant difference when compared with con-
trols (87.5 ± 69.7 vs. 118.1 ± 70.6 g/mL, p = 0.053). There was
also no signiﬁcant difference between patients with active
and inactive SLE (88.8 ± 74.4 vs. 85.5 ± 95.9 g/mL, p = 0.866).
Leptin levels in SLE patients and controls are shown in
Figs. 1 and 2. Leptin levels were signiﬁcantly higher in SLE
patients compared to controls (20.7 ± 17.1 vs. 8.0 ± 5.0 ng/mL,
p < 0.001). There was no signiﬁcant difference in leptin levels
between patients with active and inactive SLE (21.1 ± 19.8 vs.
20.4 ± 15.3 ng/mL, p = 0.874).
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Sigure 1 – Serum leptin levels (DP) in SLE patients and
ontrols.
The correlation between leptin levels and lipid proﬁle,
lood glucose and BMI  showed a positive association between
eptin levels and HDL (r = 0.34, p = 0.014) and between lep-
in levels and BMI  (r = 0.34, p = 0.014) only in SLE patients.
diponectin levels were not correlated to the variables studied
n SLE patients.
There was no signiﬁcant correlation of leptin with ESR
r = −0.062, p = 0.666) or SLEDAI (r = −0.053, p = 0.710), and there
as also no correlation of adiponectin with these variables
ESR, r = 0.047; p = 0.743 and SLEDAI, r = 0.169, p = 0.230).
No association of adiponectin with autoantibodies and
linical features of SLE was observed (Table 3). However, a sig-
iﬁcant association between low levels of leptin and positivity
or aCL and LA was observed, as well as a signiﬁcant associ-
tion between high levels of leptin and the presence of renal
nvolvement (Table 4).
iscussion
eptin is a proinﬂammatory cytokine that appears to con-
ribute to systemic inﬂammation in autoimmune rheumatic
4,5iseases, including SLE. In the present study, leptin lev-
ls were signiﬁcantly higher when compared with the
ontrol group, a ﬁnding that was also observed in several
tudies.11–13,20–23
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However, Wislowska et al.24 found no difference in serum
leptin levels between SLE patients and controls, while De Sanc-
tis et al.25 observed a signiﬁcantly lower level of leptin in
patients with SLE.
In our study, no signiﬁcant differences in adiponectin levels
between patients and controls was observed, although there
was a trend toward lower levels of adiponectin in SLE patients,
which was similar to the results found by Vadacca et al.21,22
and McMahon et al.23
Different results were found by Sada et al.12 Chung et al.20
and De Sanctis et al.,25 who observed a signiﬁcant increase in
adiponectin levels in patients with SLE. As adiponectin plays
an anti-inﬂammatory, anti-atherogenic and anti-diabetic
role,14 those studies that found a higher level of adiponectin
sought to justify this ﬁnding as a compensatory effect.20,26
One possible explanation for the different activities of
adiponectin is that low molecular weight adiponectin has
anti-inﬂammatory activity, whereas high molecular weight
adiponectin has proinﬂammatory action, the latter being most
commonly found in plasma.14,27
In the present study, there was a positive association
between leptin and BMI in patients with SLE, but not in the
control group. The same was observed by Chung et al.20 We
observed an association of leptin levels with HDL-cholesterol
but not with LDL-cholesterol and triglycerides, as found by
Chung et al.20
Regarding adiponectin, there was no correlation with any
of the variables studied, although Chung et al.20 have found
a negative association of adiponectin with BMI  and a positive
association with HDL-cholesterol.
In this study, there was no statistical correlation between
the levels of leptin and adiponectin with disease activ-
ity, measured by SLEDAI and ESR. The lack of relationship
between disease activity and leptin was also observed in other
studies.11,20,24,25,28
However, in studies conducted by Vadacca et al.,21,22 the
authors observed a correlation between leptin levels and activ-
ity indices (SLEDAI and ECLAM) in SLE, but no correlation
whatsoever of these indices with adiponectin. Although leptin
levels are higher in patients with SLE, these do not appear to
be associated with disease activity and, therefore, would not
be a marker of disease activity.
Most studies11–13,20,23–25 include patients with low disease
activity, as those with high activity are generally taking high
doses of corticosteroids and, thus, are excluded. The relation
of leptin in patients with SLE activity may be further clariﬁed
by studies involving patients with higher SLEDAI and without
prior treatment.
In this study, there was no association between ANA,
anti-ENA and anti-DNA autoantibodies with levels of lep-
tin and adiponectin, but there was an association between
low levels of leptin and the presence of LA and aCL. None
of the patients included in the study presented antiphos-
pholipid syndrome. In our literature survey, we did not ﬁnd
studies presenting a correlation between the presence of
antiphospholipid antibodies and leptin in SLE patients. Only
Garcia-Gonzalez et al.11 evaluated the presence of anti-DNA
and leptin levels, and found no correlation.
In this study, adiponectin levels were not correlated with
any clinical manifestation, but high levels of leptin correlated
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Table 3 – Association of adiponectin levels with the presence of autoantibodies and clinical manifestations in 52 patients
with systemic lupus erythematosus.
Variables (n) Presentation (n) Adiponectin p
Normal (<11 g/mL) High (≥11 g/mL)
ANA (52) Positive (47) 13 34 0.136
Negative (5) 3 2
Anti-Ro (49) Positive (22) 5 17 0.280
Negative (27) 10 17
Anti-La (49) Positive (7) 1 6 0.310
Negative (42) 14 28
Anti-Sm (49) Positive (20) 7 13 0.580
Negative (29) 8 21
Anti-RNP (50) Positive (25) 6 19 0.355
Negative (25) 9 16
Anti-DNA (45) Positive (22) 6 16 0.815
Negative (23) 7 16
aCL (37) Positive (6) 2 4 0.959
Negative (31) 10 21
LA (41) Positive (6) 2 4 0.926
Negative (35) 11 24
Clinical
manifestation (21)
Renal  (15) 5  10 0.472
CNS (2) 0  2
Cut/art (4) 2 2
ANA, antinuclear antibody; Anti-Ro, anti-SSA; Anti-La, anti-SSB; Anti-Sm, anti-Smith; Anti-RNP, anti-U1 ribonucleoprotein; Anti-DNA, anti-
CNS, deoxyribonucleic acid; aCL, anticardiolipin; LA, lupus anticoagulant; 
Chi-squared test of Pearson.
with renal involvement. Wislowska et al.24 showed a lower
level of leptin in patients with arthritis and CNS involvement
compared to patients without such manifestations. How-
ever, Kim et al.13 found no correlation between leptin levels
with clinical manifestations. Also, no studies correlating renal
involvement and leptin levels were found.
Table 4 – Association of leptin levels with the presence of autoa
systemic lupus erythematosus.
Variables (n) Presentation (n) 
Low (<3.7 ng/mL)
ANA (52) Positive (47) 11 
Negative (5) 0 
Anti-Ro (49) Positive (22) 5 
Negative (27) 4 
Anti-La (49) Positive (7) 1 
Negative (42) 8 
Anti-Sm (49) Positive (20) 5 
Negative (29) 3 
Anti-RNP (50) Positive (25) 6 
Negative (25) 3 
Anti-DNA (45) Positive (22) 5 
Negative (23) 3 
aCL (37) Positive (6) 4 
Negative (31) 5 
LA (41) Positive (6) 4 
Negative (35) 5 
Clinical
manifestation (21)
Renal (15) 4 
CNS (2) 0 
Cut/art (4) 3 
ANA, antinuclear antibody; Anti-Ro, anti-SSA; Anti-La, anti-SS B; Anti-Sm
deoxyribonucleic acid; aCL, anticardiolipin; LA, lupus anticoagulant; CNS, 
Chi-squared test of Pearson.central nervous system; Cut/art, cutaneous and articular.
Wang et al.29 demonstrated that the signaling pathway
of Jak/STAT plays an important role in the progression
of nephritis in mice models. Considering that this signal-
ing pathway is activated by leptin, maybe it could be the
explanation of the correlation of renal disease and lep-
tin.
ntibodies and clinical manifestations in 52 patients with
Leptin p
Normal (3.7–11.1 ng/mL) High (>11.1 ng/mL)
8 28 0.200
0 5
1 16 0.210
6 17
1 5 0.830
7 27
3 12 0.394
5 21
3 16 0.465
5 17
6 11 0.120
2 18
0 2 0.025
8 18
2 0 0.003
5 25
0 11 <0.001
2 0
0 1
, anti-Smith; Anti-RNP, anti-U1 ribonucleoprotein; Anti-DNA, anti-
central nervous system; Cut/art, cutaneous and articular.
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None of the patients in this study showed impaired renal
unction, although higher levels of leptin in patients with
hronic kidney disease were described in the literature.30 This
tudy did not evaluate the urinary level of leptin, and more
tudies are needed to determine whether higher leptin levels
ay be a marker of renal activity.
Currently, advances in research related to SLE show that the
dipokines may represent an important group for the discov-
ry of cytokines that help to understand the pathophysiology
f this disease and that can also serve as a serologic marker,
ssisting in the identiﬁcation of patients at risk of developing
evere forms or being a predictor of disease activity.
In conclusion, leptin levels are higher in patients with SLE
nd there was a trend to lower adiponectin levels. High lep-
in levels do not seem to reﬂect the activity of the disease.
enal involvement was the only clinical manifestation that
as associated with increased leptin levels, and there was an
nverse association of serum levels of leptin with the presence
f lupus anticoagulant and anticardiolipin. The role of leptin
n SLE needs to be better clariﬁed, and studies including larger
umbers of patients, different stages of disease and different
linical presentations are required.
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